Stem cell therapy: A promising and prospective approach in the treatment of patients with severe buergergss disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 5, 2009, Pages 552-560

  Boda, Zoltan ^a   Udvardy, Miklos ^a   Rázsó, Katalin ^a   Farkas, Katalin ^d   Tóth, Judit ^b   Jámbor, Laszlo ^b   Oláh, Zsolt ^a   Ilonczai, Peter ^a   Szarvas, Mariann ^a   Kappelmayer, Janos ^c   Veráb, Zoltan ^a   Rajnavoülgyi, Eva ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Department of Radiology ^*  (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d St Imre Univ Teaching Hospital   (Hungary)

Author keywords

Autologous bone marrowg derived stem cell therapy; Buergergss disease; Nonhealing ulcer; Therapeutic angiogenesis

Indexed keywords

CD34 ANTIGEN;

ADULT; AGED; ANALYTICAL PARAMETERS; ANGIOGENESIS; ANKLE BRACHIAL INDEX; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BUERGER DISEASE; CELL ISOLATION; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AMPUTATION; ANGIOGRAPHY; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; THROMBOANGIITIS OBLITERANS;

EID: 70449640871     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608319882     Document Type: Article

References (28)

1. Rookmaaker MB, Verhaar MC, Loomans CJ, et al. CD34+ Cells home, proliferate, and participate in capillary formation, and in combination with CD34- cells enhance tube formation in a 3-dimensional matrix. Arterioscler Thromb Vasc Biol. 2005 ; 25: 1843-1850.
2. Zhou B., Poon MC, Pu WT, Han ZC Therapeutic neovascularization for peripheral arterial diseases: advances and perspectives. Histol Histopathol. 2007 ; 22: 677-686.
3. Timmermans F., Van Hauwermeiren F., De Smedt M., et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol. 2007 ; 27: 1572-1579.
4. Case J., Mead LE, Bessler WK, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007 ; 35: 1109-1118.
5. Kolvenbach R., Kreissig C., Ludwig E., Cagiannos C. Stem cell use in critical limb ischemia. J Cardiovasc Surg (Torino). 2007 ; 48: 39-44.
6. Huang PP, Li SZ, Han MZ, et al. Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. Thromb Haemost. 2004 ; 91: 606-609.
7. Lenk K., Adams V., Lurz P., et al. Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur Heart J. 2005 ; 26: 1903-1909.
8. Kawamura A., Horie T., Tsuda I., et al. Prevention of limb amputation in patients with limbs ulcers by autologous peripheral blood mononuclear cell implantation. Ther Apher Dial. 2005 ; 9: 59-63.
9. Yang X., Wu YX, Wang HM, et al. Autologous peripheral blood stem cells transplantation in treatment of 62 cases of lower extremity ischemic disorder [in Chinese]. Zhonghua Nei Ke Za Zhi. 2005 ; 44: 95-98.
10. SÁnchez-Guijo F., GonzÁles-Porras JR, Lopez-Holgado N., et al. Peripheral endothelial progenitor cells (CD133+) for therapeutic vasculogenesis in critical limb ischaemia of the lower extremities [abstract]. Bone Marrow Transplant. 2006 ; 37: S226.
11. Kawamura A., Horie T., Tsuda I., et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs. 2006 ; 9: 226-233.
12. Tateishi-Yuyama E., Matsubara H., Murohara T., et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone marrow cells: a pilot study and a randomized controlled trial. Lancet. 2002 ; 360: 427-435.
13. Higashi Y., Kimura M., Hara K., et al. Autologous bone marrow mononuclear cell implantation improves endothelium-dependent vasodilation in patients with limb ischemia. Circulation. 2004 ; 109: 1215-1218.
14. Yamamoto K., Kondo T., Suzuki S., et al. Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: therapeutic effect by stem cell transplantation. Arterioscler Thromb Vasc Biol. 2004 ; 24: e192 - e196.
15. Durdu S., Akar AR, Arat M., Sancak T., Eren NT, Ozyurda U. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg. 2006 ; 44: 732-739.
16. Irrera G., Console G., Martino M., et al. Therapeutic angiogenesis after infusion of bone marrow mononuclear cells for Buergergss disease: case report [abstract]. Bone Marrow Transplant. 2005 ; 36: S92.
17. Bartsch T., Falke T., Brehm M., et al. Intra-arterial and intramuscular transplantation of adult, autologous bone marrow stem cells. Novel treatment for therapy-refractory peripheral arterial occlusive disease [in German]. Dtsch Med Wochenschr. 2006 ; 131: 79-83.
18. Kajiguchi M. Kondo T., Izawa H., et al. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J. 2007 ; 71: 196-201.
19. Yoder MC, Mead LE, Prater D., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007 ; 109: 1801-1809.
20. Shyu K., Chang H., Wang BW, Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical limb ischemia. Am J Med. 2003 ; 114: 85-92.
21. Rajagopalan S., Mohler ER III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomised, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003 ; 108: 1933-1938.
22. Friedrich EB, Walenta K., Scharlau J., Nickenig G., Werner N. CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res. 2006 ; 98: e20 - e25.
23. Bartunek J., Vanderheyden M., Vandekerckhove B., et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation. 2005 ; 112 (9 Suppl). 1178-1183.
24. Hill JM, Zalos G., Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003 ; 348: 593-600.
25. Kim S., Han H., Chae GT, et al. Successful stem cell therapy using multi-potent stem cells for Buergergss disease and ischemic limb disease animal model. Stem Cells. 2006 ; 24: 1620-1626.
26. Iwasaki H., Kawamoto A., Ishikawa M., et al. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation. 2006 ; 113: 1311-1325.
27. Kawamoto A., KM, Handa N., Kinoshita M., et al. A phase II/III single-blind, dose-escalation, clinical trial of autologous CD34+ cell transplantation in intractable patients with chronic critical limb ischemia. Eur Heart J. 2007 ; 28 (Suppl 1). 500.
28. Olin JW Thromboangiitis obliterans (Buergergss disease). N Engl J Med. 2000 ; 343: 864-869.